Loading organizations...
Hemex Health, based in Portland, Oregon, develops and manufactures the Gazelle diagnostic platform, a portable device for detecting and quantifying blood-based conditions such as sickle cell disease, beta thalassemia, and malaria. This technology integrates miniaturized diagnostics, innovative optics, and AI to deliver rapid, quantitative results in resource-limited settings. Since its 2021 introduction, the Gazelle platform has been adopted in over 40 countries, with thousands of readers deployed and millions of tests sold. The company's devices are utilized by public health programs, including India's National Sickle Cell Anaemia Elimination Mission across Odisha, Tamil Nadu, and Gujarat, and has received investment from Elevate Capital. Hemex Health also received FDA Breakthrough Device Designation for its Gazelle Hb Variant Test. The organization was founded in 2016 by Patti White and Peter Galen.
HEMEX has 4 tracked investments across 4 companies. The latest tracked deal is $7.6M Series B in Hemotune in April 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Apr 26, 2022 | Hemotune | $7.6M Series B | Cedric Barra | Vp%20venture%20partners, Zürcher Kantonalbank |
| Aug 12, 2020 | Scailyte AG | $4.0M Pre-Series A | Dominique Megret | 4FO Ventures, Susanne Schorsch |
| Apr 9, 2020 | Annaida Technologies | $1.0M Seed | Hemex | Business%20Angels%20Switzerland, Fongit, Privilege Ventures, Venture Kick, Z%C3%BCrcher%20Kantonalbank |
| Dec 7, 2018 | Resistell AG | $2.0M Seed | Occident | — |
